MetaCap

Janux Therapeutics (JANX) vs Sagimet Biosciences Series A (SGMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sagimet Biosciences Series A (SGMT) has outperformed Janux Therapeutics (JANX) over the past year, gaining 36.1% versus a loss of 65.0%. Sagimet Biosciences Series A is the larger company by market cap ($648.0 million vs $616.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

JANX-65.00%SGMT+36.13%
+78%+3%-72%
Nov 21, 20251 yearNov 20, 2026
JANX-19.10%SGMT-43.07%
+447%+167%-112%
Jul 10, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

JANX versus SGMT key metrics
MetricJANXSGMT
Share price$10.08$9.08
Market cap$616.73M$648.02M
1-day change-2.04%-5.61%
YTD return-26.96%+53.38%
1-year return-65.00%+36.13%
5-year return-42.92%—
EPS (TTM)$-1.59$-1.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$10.00M—
Revenue growth (YoY)-5.55%—
Net income (latest FY)$-113.63M$-51.04M
Operating margin-1576.67%—
Net margin-1136.25%—
52-week high$35.34$11.45
52-week low$10.05$4.50
Distance from 52-week high-71.48%-20.69%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+228.77%+200.33%
Average volume961.56K1.23M
Shares outstanding61.18M71.37M
Employees11416
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SGMT has outperformed JANX by 101.1 percentage points over the past year.

About Janux Therapeutics

JANX stock →

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 114 employees

About Sagimet Biosciences Series A

SGMT stock →

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

JANX vs SGMT FAQ

Which is bigger, Janux Therapeutics or Sagimet Biosciences Series A?

Sagimet Biosciences Series A (SGMT) is larger, with a market capitalization of $648.02M compared with $616.73M for Janux Therapeutics (JANX).

Which stock has performed better over the past year, JANX or SGMT?

SGMT returned +36.13% over the past 12 months, compared with -65.00% for JANX (price return, excluding dividends). Past performance does not predict future results.

Are Janux Therapeutics and Sagimet Biosciences Series A in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons